Biotech Hangout
Episode 37
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
In this episode, Daphne, Bruce, Tim and guest Jefferies’ Michael Yee discuss the latest happenings in biotech, including recent key earnings, clinical data including ASH abstracts, “BAMG (Bristol Myers Squibb, Amgen, Merck and Gilead) as the new FAANG” and ways that companies are navigating the current challenging financing environment including debt, royalties, reverse mergers & the idea of returning capital after a setback. The episode also delves into the healthy follow-on financing environment.